Physician

Gregory Carl Chipman, M.D.

According to 2025 Medicare claims, Gregory Chipman, M.D. (NPI: 1457493967) practices medical oncology in the Provo-Orem-Lehi, UT market, with the plurality of this provider's patient population coming from Utah, UT. This provider's primary affiliated billing organization is UTAH CANCER SPECIALISTS PC (NPI: 1619925369; TIN: 870519691) and primary practice location at 84062-3598. Chipman is affiliated with the Aledade 201 National MSSP (ACO ID: A5522), participating under the MSSP model.

Chipman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 244 traditional Medicare patients, billed 114,771 HCPCS/CPT codes, and received $1,897,481 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 700 prescription claims across 143 beneficiaries totaling $4,399,768 in drug costs, led by Ibrance (Palbociclib). 2022 DME data shows 27 claims. Open Payments data shows 162 records totaling $5,633. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $637,296 to $1,897,481. Similarly, Part D prescription costs have risen steadily, from $315,471 to $4,399,768. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	212	33,405	$637,296
2016	258	58,250	$1,003,139
2017	356	72,843	$1,460,077
2018	326	65,859	$1,084,033
2019	301	63,379	$1,048,808
2020	279	67,242	$1,197,054
2021	288	85,169	$1,450,264
2022	279	74,100	$1,351,449
2023	255	87,223	$1,392,258
2024	244	114,771	$1,897,481

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	109	476	$315,471
2016	133	567	$420,507
2017	175	798	$720,652
2018	178	861	$1,364,684
2019	169	889	$1,640,177
2020	160	1,013	$2,323,084
2021	144	753	$2,011,472
2022	148	664	$2,670,532
2023	145	623	$2,510,524
2024	143	700	$4,399,768

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	39	$6,097
2018	N/R	28	$533
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	35	$3,461
2022	N/R	27	$1,281
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	125	500	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	120	171	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	77	145	$12
80053	Blood test, comprehensive group of blood chemicals	169	715	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	176	812	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	50	1,379	$786,045
Xtandi	Enzalutamide	51	1,530	$719,259
Imbruvica	Ibrutinib	32	883	$497,237
Revlimid	Lenalidomide	31	861	$490,364
Brukinsa	Zanubrutinib	27	810	$398,003

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	160	$5,633	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	2	$7,071	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Gregory Carl Chipman, M.D.?

Tedicare shows public-source Medicare data for Gregory Carl Chipman, M.D. (NPI 1457493967), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gregory Carl Chipman, M.D. have ACO affiliation data?

Gregory Carl Chipman, M.D. is shown with ACO affiliation data for Aledade 201 National MSSP (MSSP, ACO ID A5522).

What billing organization is linked to Gregory Carl Chipman, M.D.?

Gregory Carl Chipman, M.D. is linked to UTAH CANCER SPECIALISTS PC (billing NPI 1619925369) in the available physician profile data.

Does Gregory Carl Chipman, M.D. have Open Payments data?

Gregory Carl Chipman, M.D. has 162 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.